OKYO Pharma Today Announces Director Acquires Shares
30 March 2023 - 5:01PM
OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the
“Company“), an ophthalmology-focused bio-pharmaceutical company
which is developing OK-101 to treat dry eye disease (“DED“) to
address the significant unmet need in this multi-billion-dollar
market, today announces that it has been notified that Panetta
Partners Limited, an entity in which Gabriele Cerrone, the
Executive Chairman has a beneficial interest, purchased 11,000 of
the Company's ADSs on NASDAQ at a price of US$1.41 per ADS (which
would be equivalent to the purchase of 715,000 ordinary shares of
no par value ("Ordinary Shares") at a price of £0.0176 each).
1. |
Details of PDMR / person closely associated |
a) |
Name |
Gabriele Cerrone |
2. |
Reason for the notification |
a) |
Position / status |
Chairman |
b) |
Initial notification /amendment |
Initial notification |
3. |
Details of the issuer |
a) |
Name |
OKYO Pharma Limited |
b) |
LEI |
213800VVN5CB56Y15A05 |
4. |
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted |
a) |
Description of the financial instrument |
ADSs representing 65 Ordinary Shares of no par value |
b) |
Identification code of the Financial Instrument |
ISIN for OKYO Pharma Limited GG00BD3FV870 |
c) |
Nature of the transaction |
Market Purchase |
d) |
Price(s) and volume(s) |
$1.41 – 11,000 |
f) |
Date of the transaction |
28 March 2023 |
g) |
Place of the transaction |
NASDAQ |
Enquiries:
OKYO Pharma Limited |
Gary S. Jacob, Chief Executive Officer |
+44 (0)20 7495 2379 |
|
|
|
Investor Relations |
Paul Spencer |
+44 (0)20 7495 2379 |
|
|
|
Broker |
Robert Emmet, Optiva Securities Limited |
+44 (0)20 3981 4173 |
Notes for Editors:
About OKYOOKYO Pharma Limited (LSE: OKYO;
NASDAQ: OKYO) is a life sciences company admitted to listing on
NASDAQ and on the standard segment of the Official List of the UK
Financial Conduct Authority and to trading on the main market for
listed securities of London Stock Exchange plc. OKYO is focusing on
the discovery and development of novel molecules to treat
inflammatory dry eye diseases and chronic pain. For further
information, please visit www.okyopharma.com.
About OK-101OK-101 is a lipid conjugated
chemerin peptide antagonist of the ChemR23 G-protein coupled
receptor which is typically found on immune cells of the eye
responsible for the inflammatory response. OK-101 was developed
using a membrane-anchored-peptide (MAP) technology to produce a
novel long-acting drug candidate for treating dry eye disease.
OK-101 has been shown to produce anti-inflammatory and
pain-reducing activities in mouse models of dry eye disease and
corneal neuropathic pain; and is designed to combat washout through
the inclusion of the lipid ‘anchor’ contained in the candidate drug
molecule to enhance the residence time of OK-101 within the ocular
environment.
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Apr 2023 to Apr 2024